StockNews.com upgraded shares of HUTCHMED (NASDAQ:HCM - Free Report) from a hold rating to a buy rating in a research report released on Friday.
HUTCHMED Stock Down 3.1 %
Shares of HCM traded down $0.47 on Friday, hitting $14.62. 44,633 shares of the stock traded hands, compared to its average volume of 106,315. HUTCHMED has a one year low of $12.84 and a one year high of $21.92. The business has a 50 day simple moving average of $14.70 and a 200 day simple moving average of $16.48. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.81 and a quick ratio of 2.68.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of HCM. Public Employees Retirement System of Ohio purchased a new position in HUTCHMED in the 3rd quarter worth about $35,000. Barclays PLC raised its holdings in shares of HUTCHMED by 1,483.6% during the fourth quarter. Barclays PLC now owns 2,407 shares of the company's stock valued at $35,000 after purchasing an additional 2,255 shares during the last quarter. Blue Trust Inc. lifted its position in HUTCHMED by 99.9% during the fourth quarter. Blue Trust Inc. now owns 7,068 shares of the company's stock valued at $102,000 after purchasing an additional 3,532 shares during the period. Summit Trail Advisors LLC boosted its holdings in HUTCHMED by 14.4% in the fourth quarter. Summit Trail Advisors LLC now owns 13,090 shares of the company's stock worth $189,000 after purchasing an additional 1,647 shares during the last quarter. Finally, OLD Mission Capital LLC bought a new stake in HUTCHMED in the 4th quarter worth approximately $230,000. 8.82% of the stock is owned by institutional investors.
About HUTCHMED
(
Get Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Featured Articles
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
